PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
A new study by researchers at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington has provided one of the most detailed analyzes so far on how alcohol affects health. The researchers reviewed data from 843 studies published up to 2023 and used a special method that...
A recent study suggests that the effects of a major surgery may go beyond pain and mobility issues, potentially causing a decline in memory and thinking abilities. Researchers followed 560 adults aged over 70 who showed no signs of dementia before undergoing major surgeries such as hip replacements...
A study published in CDC's Emerging Infectious Diseases journal Tuesday highlights a growing concern for adverse outcomes from patients who have traveled abroad to undergo cosmetic procedures. The findings underscore the need for patients considering medical procedures abroad to fully understand the...
Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company, priced a public offering of 10 million shares at $15.00 per share. The gross proceeds to Jade from the offering are expected to be $150.0 million. Jade's lead investigational candidate, JADE101, is being evaluated in a Phase 2...